Saturday 17 October 2026 Export TNGX’s income statement to Excel — free account

Tango Therapeutics, Inc.

Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 5.71% and free cash flow fell 4.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

22.04 0.66 −2.91%

Follow TNGX

Alert me

Market cap: $3.8B
P/E: 0.0×
Fwd P/E: −15.3×
Dividend yield: —
F-score: 4/9
Altman Z: 9.88
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 7.69

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	4	2	2	1	1	1	1	2	1

Insider Ownership 17.16%

Capital & Financial Ratios $m

Market Cap 3,830.00

Revenue 62.38

Net Income (123.72)

Free Cash Flow (144.25)

Net Debt (1,013.99)

Current Ratio 50.82

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (15.30)

P/S ratio 52.95

P/B ratio 3.22

Past 5Y EPS Growth —

This Y EPS Growth (63.61%)

Next Y EPS Growth (17.52%)

Next Y revenue growth (95.42%)

Next 5Y EPS Growth (29.79%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 91.48%

10-year low 10-year high

P/B against its own 10 years 53.48%

10-year low 10-year high

EV/Sales against its own 10 years 86.99%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	338	258	344	1,014
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	347	266	354	1,032

	2023	2024	2025	Q'26
Payables	3	2	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	46	38	22	20

Compound Annual Growth %

	10y	5y	3y
Sales	—	52.13%	35.89%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	55.08%	11.54%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	5	3	54	0	62
’24	6	20	12	4	42
’23	6	15	11	5	37
’22	6	6	7	6	25
’21	6	18	7	6	37

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(44)	(39)	—	—	—
’25	(42)	(37)	(31)	(30)	(139)
’24	(38)	(24)	(33)	(37)	(132)
’23	(35)	(24)	(31)	(27)	(118)
’22	(30)	(32)	(20)	(28)	(109)
’21	(14)	(8)	(21)	(17)	(60)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(44)	(39)	—	—	—
’25	(42)	(37)	(31)	(30)	(140)
’24	(38)	(24)	(34)	(37)	(132)
’23	(36)	(25)	(31)	(28)	(120)
’22	(31)	(33)	(23)	(29)	(117)
’21	(14)	(8)	(22)	(18)	(61)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.32)	(0.37)	—	—	—
’25	(0.36)	(0.35)	0.13	(0.29)	(0.87)
’24	(0.35)	(0.24)	(0.27)	(0.35)	(1.19)
’23	(0.32)	(0.23)	(0.23)	(0.32)	(1.08)
’22	(0.29)	(0.28)	(0.33)	(0.33)	(1.23)
’21	(0.29)	(0.09)	(0.28)	(0.27)	(0.94)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	9.83	8.90	3.18	2.47	2.70	1.03	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	11.83	18.84	11.00	13.03	13.01	11.20
People
People	Employees	—	—	—	—	4	91	110	140	155	137
	Revenue/emp, $m	—	—	—	—	1.91	0.41	0.23	0.26	0.27	0.46
Income, $m
Income, $m	Revenue	—	—	—	—	8	37	25	37	42	62
	Gross margin, %	—	—	—	—	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	—	—	(52)	(58)	(108)	(102)	(130)	(102)
	EBT margin, %	—	—	—	—	(678.84)	(156.43)	(434.92)	(278.18)	(309.24)	(162.85)
	Net income	—	0	—	0	(52)	(58)	(108)	(102)	(130)	(102)
	Depreciation	—	—	—	—	1	1	2	(1)	(2)	0
Per share, $
Per share, $	Revenue	—	—	—	—	0.24	0.60	0.28	0.39	0.39	0.54
	Earnings	—	—	—	—	(1.63)	(0.94)	(1.23)	(1.08)	(1.19)	(0.87)
	Cash flow	—	—	—	—	2.19	(0.96)	(1.24)	(1.25)	(1.20)	(1.20)
	Capex	—	—	—	—	(0.03)	(0.03)	(0.09)	(0.02)	(0.01)	(0.01)
	Free cash flow	—	—	—	—	2.16	(0.99)	(1.33)	(1.26)	(1.21)	(1.20)
	Book value	—	—	—	—	1.21	5.55	2.84	2.68	1.83	2.98
	Shares, m	—	—	—	—	32	62	88	95	109	116
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	18.34	25.82	25.84	8.02	16.50
	P/B	—	—	—	—	1.51	1.97	2.57	3.73	1.69	2.97
	EV/Sales	—	—	—	—	0.00	5.23	11.07	16.59	1.89	10.99
	EV/FCF	—	—	—	—	0.00	(3.16)	(2.36)	(5.07)	(0.60)	(4.90)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	70	(60)	(109)	(118)	(132)	(139)
	Capex	—	—	—	—	(1)	(2)	(8)	(2)	(1)	(1)
	Free cash flow	—	—	—	—	69	(61)	(117)	(120)	(132)	(140)
Balance, $m
Balance, $m	Working capital	—	—	—	—	153	452	320	301	228	332
	Total debt	—	—	—	—	8	2	41	—	—	—
	Net debt	—	—	—	—	(190)	(486)	(367)	(338)	(258)	(344)
	Shareholders’ equity	—	—	—	—	39	345	249	253	200	346
Returns, %
Returns, %	ROA	—	—	—	0.00	(50.15)	(16.46)	(23.10)	(24.25)	(36.24)	(28.41)
	ROIC	—	—	—	—	0.00	0.00	0.00	0.00	0.00	(2,661.91)
	ROE	—	—	—	—	(20.50)	(30.38)	(36.41)	(40.49)	(57.58)	(37.23)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DNTH Dianthus Therapeutics, Inc.	$4.2B	— (loss-making)	— (loss-making)	+294.30% (above 0%: growing)	n/m	−105.37% (below 0%: shrinking)	100.00%	(8,079.11%)	Compare
EWTX Edgewise Therapeutics, Inc.	$4.2B	— (loss-making)	—	—	n/m	−30.24% (below 0%: shrinking)	0.00%	0.00%	Compare
ABCL AbCellera Biologics Inc.	$4.1B	— (loss-making)	— (loss-making)	−76.29% (below 0%: shrinking)	n/m	+151.98% (above 0%: growing)	100.00%	(1,550.05%)	Compare
LEGN Legend Biotech Corporation Sponsored ADR	$3.8B	— (loss-making)	112×	+51.90% (above 0%: growing)	n/m	−26.79% (below 0%: shrinking)	64.54%	14.37%	Compare
TNGX Tango Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−4.58% (below 0%: shrinking)	0.00%	0.00%
RLAY Relay Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−95.44% (below 0%: shrinking)	n/m	+2.13% (above 0%: growing)	100.00%	(25,949.71%)	Compare
ARQT Arcutis Biotherapeutics, Inc.	$3.7B	131×	196×	+59.33% (above 0%: growing)	n/m	+227.96% (above 0%: growing)	91.58%	12.65%	Compare
TLX Telix Pharmaceuticals Limited	$3.6B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
TARS Tarsus Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	+69.41% (above 0%: growing)	n/m	+288.08% (above 0%: growing)	93.03%	(11.45%)	Compare
Median of peers	$3.8B	—	—	+55.62%	—	−12.33%	93.03%	(11.45%)

All 614 Biotechnology stocks →

Tango Therapeutics, Inc. (TNGX) key facts

Strength: Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
Tango Therapeutics, Inc. (TNGX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TNGX traded at $22.04, a market capitalization of $3.8 billion.
Return on equity was −37.2% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 9.88 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.